International
1. Kurhe Y,MaheshR, Devadoss T. Novel 5-HT3receptorantagonist QCM-4 attenuates depressive-like phenotype associated with obesity in high-fat-diet-fed mice. Psychopharmacology 2017; 234, 1165-1179. (Springer) (IF-3.87)
2. Mundra S, Thakur V, Bello A. M, Rathore S, Asad M, Wei L, Yang J, Chakka S. K, Mahesh R, Malhotra P, Mohmmed A, Kotra L. P. A novel class of Plasmodial ClpP protease inhibitors as potential antimalarial agents. Bioorganic & Medicinal Chemistry 2017; 25, 5662-5677 (IF-2.793)
3. Bhatt S, Mahesh R, Devadoss T, Jindal A. Neuropharmacological evaluation of a novel 5-HT3 receptor antagonist (4-benzylpiperazin-1-yl)(3-methoxyquinoxalin-2-yl) methanone (6g) on lipopolysaccharide-induced anxiety models in mice. Journal of Basic and Clinical Physiology and Pharmacology 2016, Volume 28, Issue 2, Pages 101– 106, ISSN (Online) 2191-0286, ISSN (Print) 0792-6855, (De Gruyter)
4. Bhatt S, Mahesh R, Jindal A, Devadoss T. Neuropharmacological and neurochemical evaluation of Nn-propyl-3- ethoxyquinoxaline-2- carboxamide (6n): a novel serotonergic 5-HT3 receptor antagonist for co-morbid antidepressant-and anxiolytic-like potential using traumatic brain injury model in rats. Journal of Basic and Clinical Physiology and Pharmacology 2016 Volume 28, Issue 2, Pages 93–100, ISSN (Online) 2191-0286, ISSN (Print) 0792-6855, (De Gruyter)
5. Kurhe Y, Mahesh R. Pioglitazone, a PPAR-ϒ agonist rescues depression associated with obesity using chronic unpredictable mild stress model in experimental mice. Neurobiology of Stress 2016; 3, 114-121. (Elsevier) (IF-1.0)
6. Bhatt S, Bagal SM, Butola S, Dhar AK, Mahesh R. Antidepressant-and anxiolytic-like effect of novel 5-hydroxytryptamine3 receptor antagonist 2-[4-(3-chlorophenyl) piperazin-1-yl]-1, 8-naphthyridine-3-carboxylic acid (7e)-: An approach using rodent behavioral antidepressant and anxiolytic test battery. International Journal of Nutrition, Pharmacology, Neurological Diseases 2016; 6, 81-89. (Medknow) (IF-0.6)
7. Gupta D, Prabhakar V, Radhakrishnan M. 5HT3 receptors: Target for new antidepressant drugs. Neuroscience & Biobehavioral Reviews 2016; 64, 311-325. (Elsevier) (IF-10.52)
8. Gupta D, Thangaraj D, Radhakrishnan M. A novel 5HT3 antagonist 4i (N-(3-chloro-2-methylphenyl)quinoxalin-2-carboxamide) prevents diabetes-induced depressive phenotypes in mice: Modulation of serotonergic system. Behavioral Brain Research 2016; 297, 41-50. (Elsevier) (IF-3.0)
9. Kurhe Y, Mahesh R. Ondansetron attenuates co-morbid depression and anxiety associated with obesity by inhibiting the biochemical alterations and improving serotonergic neurotransmission. PharmacologyBiochemistryandBehavior 2015;136, 107-116. (Elsevier) (IF-2.78)
10. Mundra S, Mahesh R. Pyridine-based microwave assisted one-pot synthetic protocol for the synthesis of ethyl 3-substituted-4-oxo-2-thioxo-1,2,3,4-tetrahydropyrimidine-5-carboxylates. Research on Chemical Intermediates 2016; 42, 4207-4219 (Springer) (IF- 1.3)
11. Kurhe Y, Mahesh R. Mechanisms linking depression co-morbid with obesity: An approach for serotonergic type 3 receptor antagonists as novel therapeutic intervention. Asian Journal of Psychiatry 2015; 17, 3-9. (Elsevier) (IF-0.6)
12. Chakka S. K, Kalamuddin M, Mundra S, Mahesh R, Malhotra P, Mohmmed A, Kotra L. P. Identification of novel class of falcipain-2 inhibitors as potential antimalarial agents. Bioorganic & Medicinal Chemistry 2015; 23, 2221-2240 (Elsevier) (IF-3.3)
13. Gupta D, Mahesh R, Kurhe Y. Effect of a novel 5-HT3 receptor antagonist 4i, in corticosterone-induced depression-likebehavior and oxidative stress in mice. Steroids 2015; 96, 95-102. (Elsevier) (IF-2.71)
14. Jindal A, Mahesh R, Bhatt S. Etazolate, a Phosphodiesterase 4 enzyme inhibitor produces antidepressant-like effects by blocking the behavioral, biochemical, neurobiological deficits and histological abnormalities in hippocampus region caused by olfactory bulbectomy. Psychopharmacology, 2015; 232, 623-637. (Springer) (IF-3.396)
15. Jindal A, Mahesh R, Bhatt S. Type 4 phosphodiesterase enzyme inhibitor, rolipram rescues behavioral deficits in olfactory bulbectomy models of depression: Involvement of hypothalamic-pituitary-adrenal axis, cAMP signaling aspects and antioxidant defense system. Pharmacology Biochemistry and Behavior 2015; 132, 20-32. (Elsevier) (IF-2.78)
16. Kurhe Y, Mahesh R, Devadoss T. QCM-4, a 5-HT3 receptor antagonist ameliorates plasma HPA axis hyperactivity, leptin resistance and brain oxidative stress in depression and anxiety-like behavior in obese mice. Biochemical and Biophysical Research Communications 2015; 456, 74-79. (Elsevier) (IF-2.281)
17. Mundra S, Mahesh R. Evaluation of novel 1-(4-(substituted)piperazin-1-yl)-2-(phenylamino)ethanone derivatives as Falcipain-2 inhibitors. Journal of young Pharmacist 2015; 7, 96-105. (Elsevier) (IF-0.5)
18. Dhar AK, Mahesh R, Jindal A, Bhatt S. Piperazine analogues of naphthyridine-3-carboxamides and indole-2-carboxamides: Novel 5-HT3 receptor antagonists with antidepressant like activity, Archive Der Pharmazie 2015; 348, 34-45. (Wiley Online Library) (IF-1.39)
19. Kurhe Y, Mahesh R, Gupta D, Thangaraj D. Effect of (4a) a novel 5-HT3 receptor antagonist on chronic unpredictable mild stress induced depressive-like behavior in mice: an approach using behavioral tests battery. Journal of Basic and Clinical Physiology and Pharmacology, 2015; 26, 25-33. (De Gruter)(IF-0.6)
20. Mahesh R, Mundra S, Devadoss T. Design, synthesis and evaluation of 2-(4-(substituted benzoyl)-1,4-diazepan-1-yl)-N phenylacetamide derivatives as a new class of falcipain-2 inhibitors. Arabian Journal of Chemistry 2014; 20, 212-224. (Elsevier) (IF-2.7)
21. Gupta D, Mahesh R, Kurhe Y. Ondansetron, a 5HT-3 receptor antagonist reverses depression andanxiety-likebehavior in streptozotocin-induced diabetic mice: Possible implication of serotonergic system. European Journal of Pharmacology 2014; 744, 59-66. (Elsevier) (IF- 2.754)
22. Dhar AK, Mahesh R, Jindal A, Devadoss T, Bhatt S. Design, Synthesis, and Pharmacological Evaluation of Novel 2-(4-substituted piperazin-1-yl)1, 8 Naphthyridine 3-Carboxylic Acids as 5-HT3 Receptor Antagonists for the Management of Depression. Chemical Biology & Drug Design 2014; 84, 721-31. (Willey) (IF-2.50)
23. Kurhe Y, Mahesh R, Gupta D, Devadoss T. QCM-4, a serotonergic type 3 receptor modulator attenuates depression co-morbid with obesity in mice: An approach based on behavioral and biochemical investigations. European Journal of Pharmacology 2014; 740, 611-618. (Elsevier) (IF-2.75).
24. Kurhe Y, Mahesh R, Gupta, D. Ondansetron attenuates depression co-morbid with obesity in obese mice subjected to chronic unpredictable mild stress; an approach using behavioral battery tests. Metabolic Brain Disease 2014; 29, 701-710. (Springer) (IF-2.39).
25. Gupta, Deepali; Radhakrishnan, Mahesh; Kurhe, Yeshwant; Anxiolytic-like effects of alverine citrate in experimental mouse models of anxiety, European journal of pharmacology, 742 - 94-101 2014, Elsevier
26. Gupta D, Mahesh R, Kurhe Y, Thangaraj D, Prabhakar V, Kanade P. Antidepressant-like effects of6z,a novel5HT3 receptorantagonistin acute andchronicmouse models of depression. Acta Pharmacologica Sinica 2014; Accepted. (Nature) (2.496).
27. Kurhe Y, Mahesh R, Gupta D. Effect of a Selective Cyclooxygenase Type 2 Inhibitor Celecoxib on Depression Associated with Obesity in Mice: An Approach Using Behavioral Tests. Neurochemical Research 2014; 39:1395-1402. (Springer) (IF-2.55)
28. Bhatt S, Mahesh R, Jindal A, Devadoss T. Protective effects of a novel 5-HT3 receptor antagonist, N-n-butyl-3-methoxy quinoxaline-2-carboxamide (6o) against chronicunpredictable mild stress–induced behavioral changes and biochemical alterations. Pharmacology Biochemistry Behavior 2014; 122: 234-239. (Elsevier) (IF-2.75)
29. Bhatt S, Mahesh R, Jindal A, Devadoss T. Neuropharmacological Effect of Novel 5-HT3 Receptor Antagonist, N-n-propyl-3-ethoxyquinoxaline-2-carboxamide (6n) on Chronic Unpredictable Mild Stress-Induced Molecular and Cellular Response : Behavioural and BiochemicalEvidences. Pharmacological Reports 2014; 66: 804-810. (Elsevier) (IF-1.96)
30. Gupta D, Radhakrishnan M, Thangaraj D, Kurhe Y. Antidepressant and anti-anxiety like effects of 4i (3-Chloro-2-methylphenyl) quinoxalin-2-carboxamide), a novel 5-HT receptor antagonist in acute and chronic neurobehavioral rodent models. European Journal of Pharmacology 2014; 735: 59-67. (Elsevier) (IF-2.592)
31. Gupta D, Radhakrishnan M, Kurhe Y. Insulin reverses anxiety-like behavior evoked by streptozotocin-induced diabetes in mice. Metabolic Brain Disease, 2014; 29, 737-46. (Springer) (IF-2.33)
32. Gupta D, Kurhe Y, Radhakrishnan M. Antidepressant effects of insulin in streptozotocin induced diabetic mice: Modulation of brain serotonin system. Physiology & Behavior 2014; 129: 73-78. (Elsevier) (IF-3.1)
33. Mahesh R, Dhar AK, Jindal A, Bhatt S. Design, synthesis and evaluation of anti depressant activity of novel 2-methoxy 1, 8 naphthyridine 3-carboxamides as 5-HT3 receptor antagonists. Chemical Biology & Drug Design 2014; 83, 583-91. (Wiley Online Library) (IF-2.50)
34. Kurhe Y, Mahesh R, Gupta D, Thangaraj D. QCM-4 a novel 5-HT3 antagonist attenuates the behavioral and biochemical alterations on chronic unpredictable mild stress model of depression in Swiss albino mice. Journal of Pharmacy and Pharmacology 2014; 66, 122-32. (Wiley Online Library) (IF-2.03)
35. Bhatt S, Mahesh R, Jindal A, Devadoss T. Neuro-pharmacological evaluation of structurally novel 5-hydroxytryptamine type 3 receptor antagonist, N-n-propyl-3-ethoxyquinoxaline-2-carboxamide (6n) for its anxiolytic potential. International Journal of Nutrition, Pharmacology, Neurological Diseases 2013; 3, 383-387. (Medknow)
36. Jindal A, Mahesh R, Bhatt S. Etazolate rescues behavioral deficits in chronic unpredictable stress model: Modulation of hypothalamic-pituitary-adrenal axis activity and brain-derived neurotrophic factor level. Neurochemistry International 2013; 63, 465-75. (Elsevier) (IF- 2.659)
37. Mahesh R, Dhar AK, Jindal A, Bhatt S. 2-(4-substituted piperazin-1-yl)-1,8-naphthyridine-3-carboxylic acids: Novel 5-HT3 receptor antagonists with anxiolytic like activity in rodent behavioral models. Canadian Journal of Physiology and Pharmacology 2013; 91, 848-54. (NRC Research Press) (IF- 1.556)
38. Gautam BK, Jindal A, Dhar AK, Mahesh R. Antidepressant - Like Activity of 2-(4-phenylpiperazin-1-yl)-1, 8-naphthyridine-3-carboxylic acid (7a), a 5 -HT(3) Receptor Antagonist in Behaviour Based Rodent Models: Evidence for the Involvement of Serotonergic System. Pharmacology Biochemistry and Behavior 2013; 109, 91–97. (Elsevier) (IF-2.608)
39. Jindal A, Mahesh R, Bhatt S. Etazolate, a phosphodiesterase 4 inhibitor reverses chronic unpredictable mild stress-induced depression-like behavior and brain oxidative damage. Pharmacology Biochemistry and Behavior 2013; 105, 63-70. (Elsevier) (IF-2.608)
40. Jindal A, Mahesh R, Gautam B. Anxiolytic-like effect of linezolid, an oxazolidinone class antibiotic in experimental mouse models of anxiety. Progress in Neuro-Psychopharmacology & Biological Psychiatry 2013; 40, 47-53. (Elsevier) (IF-3.552)
41. Jindal A, Mahesh R, Gautam B, Bhatt S, Pandey D. Antidepressant-like effect of etazolate, a cyclic nucleotidePhosphodiesterase4inhibitor –anapproach usingrodent behavioral antidepressanttestsbattery. EuropeanJournal of Pharmacology 2012;689, 125-131. (Elsevier) (IF-2.592)
42. Mahesh R, Devadoss T, Pandey DK, Dhar AK Sudali M, Mundra S, Bhatt S, Jindal A. Ligand-Based Design, Synthesis and Pharmacological Evaluation of 3-Methoxyquinoxalin-2-Carboxamides as Structurally Novel Serotonin Type-3 Receptor Antagonists. Archive Der Pharmazie 2012; 345, 687-94. (Wiley Online Library) (IF-1.54)
43. Mahesh R, Jindal A, Gautam B, Bhatt S, Pandey D. Evaluation of anti-depressant-like activity of linezolid, an oxazolidinone class derivative – An investigation using behavioral tests battery of depression. Biochemical and Biophysical Research Communications 2011; 409, 723-726. (Elsevier) (IF-2.40)
44. Mahesh R, Devadoss T, Pandey DK, Bhatt S. Discovery of newer anti-depressants from structurally novel 5-HT3 receptor antagonists: Design, synthesis and pharmacological evaluation of 3-ethoxyquinoxalin-2-carboxamides. Bioorganic & Medicinal Chemistry Letters 2011; 21, 1253-1256. (Elsevier) (IF-2.90)
45. Mahesh R, Devadoss T, Pandey DK, Yadav SK. Quinoxaline-2-Carboxamides: Synthesis and Pharmacological Evaluation as Serotonin Type-3 (5-HT3) receptor Antagonists. Journal of Enzyme Inhibition and Medicinal Chemistry 2011; 26, 610-615. (Informa Health Care) (IF-1.49)
46. Mahesh R, Dhar AK, Tarasasank, TVNV, Thirunavukkarasu S, Devadoss T. Citric acid: An efficient and green catalyst for rapid pot synthesis of quinoxaline derivatives at room temperature. Chinese Chemical Letters 2011; 22, 389-392. (Elsevier) (IF-1.21)
47. Pandey DK, Mahesh R, Kumar AA, Rao VS, Muralidharan A, Rajkumar R. A novel 5-HT2A receptor antagonist exhibits antidepressant-like effects in a battery of rodent behavioural assays: approaching early-onset antidepressants. Pharmacology Biochemistry and Behavior 2010; 94, 363-373. (Elsevier) (IF-2.75)
48. Devadoss T, Pandey DK, Mahesh R, Yadav SK. Effect of acute and chronic treatment with QCF-3 (4-benzyl pipirazin-1-yl) (quinoxalin-2-yl) methanone, a novel 5-HT3 receptor antagonist, in animal models of depression. Pharmacological Reports 2010; 62, 245-257. (Elsevier) (IF-1.96)
49. Mahesh R, Devadoss T, Pandey DK, Bhatt S, Yadav SK. Design, Synthesis and Structure Activity Relationship of Novel Quinoxalin-2-carboxamides as 5-HT3 Receptor Antagonists for the Management of Depression. Bioorganic & Medicinal Chemistry Letters 2010; 20, 6773-6776. (Elsevier) (IF-2.90)
50. Mahesh R, Pandey DK, Gautam B. Traumatic Brain Injury: Severity, Pathophysiology and Neurobehavioural Outcome. Pharmacologyonline Letters 2010; 1, 546-555. (IF-0.16)
51. Mahesh R, Pandey DK, Bhatt S, Gautam B. Depression Associated Disorders: Comorbidity, Neurobiological and Neurobehavioural Link. Pharmacologyonline Letters 2010; 1, 386-405. (IF-0.16)
52. Mahesh R, Pati D, Pandey DK, Kurdekar V, Jadhav HR. Anti-depressant-like activity of Mucuna Pruriens, a traditional Indian herb in animal models of depression. Pharmacologyonline Archives 2010; 1, 537-551. (IF-0.16)
53. Rajkumar R, Mahesh R. The auspicious role of the 5-HT3 receptor in depression: A probable neuronal target? Journal of Psychopharmacology 2010; 24, 455-469. (Sage Journals) (IF-3.37)
54. RajkumarR, PandeyDK, MaheshR, RadhaR. 1-(m-Chlorophenyl) piperazineInduces Depressogenic-like Behaviour in Rodents by inhibiting the neuronal 5-HT2A receptors: Proposal of a Modified Rodent Anti-depressant assay.European Journal of Pharmacology 2009; 608, 32-41. (Elsevier) (IF-2.592)
55. Pandey DK, Yadav SK, Mahesh R, Ramamoorthy R. Depression-like and anxiety-like behavioural aftermaths of impact accelerated traumatic brain injury in rats: A model of comorbid depression and anxiety. Behavioural Brain Research 2009; 205, 436-442. (Elsevier) (IF-3.32)
56. Pandey DK, Mahesh R. Depression: Current Therapy and novel Anti-depressant Drug Targets. Pharmacologyonline Letters 2009; 3, 993-1012. (IF-0.16)
57. Bhatt S, Mahesh R, Pandey DK, Pai KSR TAFI: A Potential Target for Fibrinolytic Drugs. Pharmacologyonline Letters 2009; 3, 770-781. (IF-0.16)
58. Ramamoorthy R, Mahesh R, Borah M. Anti-depressant-like effects of serotonin type-3 antagonist, ondansetron: an investigation in behaviour-based rodent models. Behavioural Pharmacology 2008; 19, 29-40. (Lippincott Williams and Wilkins) (IF-2.30)
59. Pandey DK, Ramamoorthy R, Mahesh R, Radha R. Depressant-like effects of Parthenolide in rodent behavioural anti-depressant test battery. Journal of Pharmacy and Pharmacology 2008; 60, 1643-1650. (Wiley Online Library) (IF-2.03)
60. Rajkumar R, Mahesh R. Assessing the Neuronal Serotonergic Target based Anti-depressant Stratagem: Impact of in vivo Interaction Studies and Knockout models. Current Neuropharmacology 2008; 6, 215-234. (Bentham Science)(IF-3.08)
61. Mahesh R, Rajkumar R, Minasri B, Perumal V. Potenatial anti-depressants; Pharmacology of 2 (4-methyl piperazine -1yl) -1, 8 naphthyridine -3-carbonitrile in rodent behavioural models. Pharamzie 2007; 63, 23-30. (Govi-Verlag) (IF-0.96)
62. Mahesh R, Perumal VR, Pandi, PV. Microwave–assisted solvent–free synthesis of 3-[(4-substitutedpiperazin-1-yl) alkyl] imidazo [2, 1-b][1,3] benzothiazol-2 (3H)-ones as Serotonin3 (5-HT3) receptor antagonists. Pharmazie 2005; 60, 411-414. (Govi-Verlag) (IF-0.96)
63. Mahesh R, Perumal VR, Pandi, PV. Cancer chemotherapy-induced nausea and vomiting: role of mediators, development of drugs and treatment methods. Pharmazie 2005; 60, 83-96. (Govi-Verlag) (IF-0.96)
64. Mahesh R, Perumal VR, Pandi PV. Microwave assisted synthesis of 2- (4-substituted piperazin-1-yl)-1,8-naphthyridine-3-carbonitrile as a new class of serotonin 5-HT3 receptor antagonists. Bioorganic Medicinal Chemistry Letter 2004; 14, 5179-5181. (Elsevier) (IF-2.90)
65. Mahesh R, Perumal V, Pandi PV. Pharmacophore Based Synthesis of 3-Chloroquinoxaline-2-carboxamides as Serotonin3 (5-HT3) Receptor Antagonist. Biological and Pharmaceutical Bulletin 2004: 27, 1403-1405. (The Pharmaceutical Society of Japan) (IF-1.849)
National
66. Kurhe Y, Mahesh R (2017). Ondansetron ameliorates depression associated with obesity in high fat diet fed experimental mice: an investigation based on the behavioral, biochemical and molecular approach. Indian J Pharmacol 2017;49,290-296. (Medknow) (IF-0.68)
67. Mundra S, Mahesh R. Insignificant in vitro falcipain-2 inhibitory activity of novel 2-(4-(substituted benzoyl) piperazine-1-yl)-N-phenylacetamide derivatives. Journal of Pharmaceutical Negative Results 2015; 6, 20-26. (Medknow)
68. Prabhakar V, Gupta D, Kanade P, Radhakrishnan M. Diabetes-associated depression: The serotonergic system as a novel multifunctional target. Indian Journal of Pharmacology 2015; 47, 4-10. (Medknow) (IF-0.68)
69. Kurhe Y, Mahesh R, Devadoss T, Gupta D. Antidepressant-like effect of a novel 5-HT3 receptor antagonist N-(benzo [d] thiazol-2-yl)-3-ethoxyquinoxalin -2-carboxamide 6k using rodents behavioral battery tests.Journal of Pharmacology & Pharmacotherapeutics 2014; 5, 197-202. (Medknow) (IF-0.68)
70. Kurhe YV, Mahesh R, Thangaraj D, Gupta D. Anti-anxiety effect of a novel 5-HT3 receptor antagonist N-(benzo[d]thiazol-2-yl)-3-ethoxyquinoxalin-2-carboxamide
(6k)using battery tests for anxiety in mice. Indian Journal of Pharmacology 2014; 46, 100-104.
(Medknow) (IF-0.68)
71. Bhatt S, Mahesh R, Jindal A, Devadoss T, Dhar AK. Neuropharmacological evaluation of a novel 5-HT3 receptor antagonist (6g) on chronic unpredictable mild stress-induced changes in behavioural and brain oxidative stress parameters in mice. Indian Journal of Pharmacology 2014; 46, 191-196. (Medknow) (IF-0.58)
72. Jindal A, Mahesh R, Bhatt S. Anxiolytic-like effect of etazolate, a type 4 phosphodiesterase inhibitor in experimental models of anxiety. Indian Journal of Experimental Biology 2013; 51, 444-449. (NISCAIR) (IF-1.195)
73. Bhatt S, Mahesh R, Jindal A, Devadoss T. Anti-depressant like activity of N-n-butyl-3-methoxyquinoxaline-2-carboxamide (6o) a 5-HT3 receptor antagonist. Indian Journal of Experimental Biology 2013; 51, 435-443. (NISCAIR) (IF-1.195)
74. Bhatt S, Mahesh R, Jindal A, Devadoss T. Anxiolytic-like effect of N-n-butyl-3-methoxyquinoxaline-2-carboxamide (6o) in experimental mouse models of anxiety. Indian Journal of Experimental Biology 2013; 51, 510-514. (NISCAIR) (IF-1.195)
75. Bhatt S, Mahesh R, Jindal A, Devadoss T. Antidepressant- like effect of novel 5-HT3 receptor antagonist N-n-butyl-3- ethoxyquinoxalin-2-carboxamide (6p)- an approach using rodent behavioral antidepressant tests battery. Indian Journal of Pharmacology 2013; 45, 348-353. (Medknow) (IF-0.58)
76. Kurhe YV, Mahesh R, Gupta D, Thangaraj D. Effect of a novel 5-HT3 receptor antagonist 3-methoxy-n-p-tolylquinoxalin-2-carboxamide (QCM-4) on the acute and chronic rodent models of depression. International Journal of Pharmacy and Pharmaceutical Sciences 2013; 5, 567-573. (Academic Sciences)(IF-0.91)
77. Gupta D, Radhakrishnan M, Bhatt S, Kurhe Y. Role of Hypothalamic-pituitary-adrenal-axis in Affective Disorders: Anti-depressant and Anxiolytic Activity of Partial 5-HT1A Agonist in Adrenalectomised Rats.Indian Journalof Psychological Medicines 2013; 35, 290-8. (Medknow)
78. Bhatt S, Mahesh R, Devadoss D, Jindal A. Anxiolytic-Like Effect of (4-benzylpiperazin-1-yl)(3-methoxyquinoxalin-2-yl)methanone (6g) in Experimental Mouse Models of Anxiety. Indian Journal of Pharmacology 2013; 45, 248-251. (Medknow) (IF-0.58)
79. Mahesh R, Bhatt S, Devadoss T, Jindal AK, Gautam BK, Dhar AK, Pandey DK. Anti-depressantLike EffectofNovel 5-HT3 Receptor Antagonist, (4-benzylpiperazin-1-yl)(3-methoxyquinoxalin-2-yl)methanone (6g) in Acute and Chronic Animal Models of Depression. Indian Journal of Pharmaceutical Education and Research, 2013; 47, 71-81. (APTI) (IF-0.15)
80. Kumar B, Jindal A, PandeyDK, Bhatt S, Devadoss D, Mahesh R. Antidepressant and anxiolytic-like effects of 4n, a novel 5-HT3 receptor antagonist using behaviour based rodent models. Indian Journal of Experimental Biology 2012; 50, 625-632. (NISCAIR) (IF-1.195)
81. Mahesh R, Kumar B, Jindal A, Bhatt, S, Devadoss T, Pandey DK. Antidepressant- like activity of (4-phenylpiperazin-1-yl) (quinoxalin-3-yl) methanone (4a), a Novel5-HT3 receptor antagonist: An investigation in behaviour-based rodent models of depression. Indian Journal of Pharmacology, 2012; 44, 560-565. (Medknow) (IF-0.58)
82. Jindal A, Mahesh R, Gautam B, Bhatt S, Pandey D. Evaluation of anti-diabetic activity of methanolic extract from the bark of Atalantia monophylla (Linn.) in alloxan-induced diabetic mice. International Journal of Green Pharmacy 2012; 6, 133-137. (Medknow)
83. Mahesh R, Bhatt S, Devadoss T, Jindal AK, Gautam BK, Pandey DK. Antidepressant Potential of 5-HT3 Receptor Antagonist, N-n-propyl-3-ethoxyquinoxaline-2-carboxamide (6n). Journal of Young Pharmacist 2012; 4, 235-244. (Elsevier)
84. Jindal A, Mahesh R, Singh K, Bhatt S, Gautam, B; Pandey D. Ameliorative Effect of Wortmannin and Rapamycin Treatment on Obesity Markers in High Fat Diet feed rats. Indian Journal of Pharmaceutical Education and Research 2011; 45, 333-338. (APTI) (IF-0.15)
85. Mahesh R, Pandey DK, Bhatt S, Gautam B. Anti-depressant like Effect of Pimozide in Acute and Chronic Animal Models of Depression. Indian Journal of Pharmaceutical Education and Research 2011; 45, 46-53. (APTI) (IF-0.15)
86. Gupta D, Devadoss T, Bhatt S, Gautam B, Jindal A, Pandey D, Mahesh R. Antidepressant like effect of a novel serotonin type-3 (5HT3) receptor antagonist in rodent models of depression. Indian Journal of Experimental Biology, 2011; 49, 619-626. (NISCAIR) (IF-1.195)
87. Chaudhary S, Mahesh R, Gautam B, Jindal A, Bhatt S. Serotonin 5-HT6 Receptor: A Potential Target For Cognition. International Research Journal of Pharmacy 2010; 1, 7-18. (Moksha Publishing House)
88. Mahesh R, Aprna A, Ramakrishnan V, George J, Pandey DK. Demographic Study On Disease Prevalence And Their Treatment Pattern In A Local Hospital Of A Semi-Urban Community.InternationalJournalofResearchin Ayurveda and Pharmacy2010; 1,569-564. (Moksha Publishing House)
89. Mahesh R, Devadoss T, Pandey DK, Baldev G, Jindal A, Shvetank B. Depression Associated Comorbid Cardiovascular And Metabolic Complications International. Journal of Research in Ayurveda and Pharmacy 2010; 1, 23-32. (Moksha Publishing House)-Invited article
90. Mahesh R, Sharma P, Gautam BK, Bhatt S, Pandey DK. Antidepressant-like activity of cannabinoid type-1 receptor antagonist, rimonabant: behavioural investigation in animal model of depression. International Journal of Pharma and Biosciences 2010; 1, 1-13. (Indian Science)-Invited article
91. Mahesh R, Pandey DK, Katiyar S, Kukade G, Viyogi S, Rudra A. Effect of Anti-depressants on neuro-behavioural consequences following impact accelerated traumatic brain injury in rats. Indian Journal of Experimental Biology 2010; 48, 466-473. (NISCAIR) (IF-1.195)
92. PandeyDK, Pati D, Joshi A, Mahesh R. Chronic Unpredictable Stress: Possible Animal Model of Comorbid Depression. International Journal of Preclinical and Pharmacy Research 2010; 1, 54-65. (Indian Science)-Invited article
93. Mahesh R, Shruti V, Pandey DK, Yadav SK. Evaluation of Anti-depressant and Analgesic- Like Activity of Ondansetron in Rodents model of Comorbid Pain and Depression. Indian Journal of Pharmaceutical Education and Research 2010; 44, 160-170. (APTI) (IF-0.15)
94. Gautam BK, Rana M, Pandey DK, Mahesh R, Singh M. The Possible Role of PI3K/Akt Pathway in Partial Abdominal Aortic Constriction (PAAC) Induced Pathological Cardiac Hypertrophy. International Journal of Pharma Recent Research 2009; 1, 1-11.
95. Rajkumar R, Mahesh R. Behavioural Investigation of Ondansetron in Rodent Models: Are 5-HT3 Receptors Potential Neuronal Targets of Depression? AAPS J 2007; 9(S2), Abstract no M1160
96. Mahesh R, Perumal VR. Microwave-induced Mannich reaction– Synthesis of some Mannich derivatives of p-aminophenol. Indian Journal of Chemistry 2004; 43, 1012-1014. (NISCAIR)